Company Overview of GlycoVaxyn AG
GlycoVaxyn AG, a vaccine biopharmaceutical company, engages in the development and manufacture of next-generation bio-conjugate vaccines against bacterial infections utilizing its recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. GlycoVaxyn AG was founded in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.
Founded in 2004
41 44 733 85 85
41 44 733 85 74
Key Executives for GlycoVaxyn AG
Similar Private Companies By Industry
|Kuros Biosurgery AG||Europe|
|Rapid Pharmaceuticals AG||Europe|
|CYPA Laboratoire de cytologie et de pathologie cliniques SA||Europe|
|Delenex Therapeutics AG||Europe|
|TLT Medical Ltd.||Europe|
Recent Private Companies Transactions
February 11, 2015
To contact GlycoVaxyn AG, please visit www.glycovaxyn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.